<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690141</url>
  </required_header>
  <id_info>
    <org_study_id>eFT508-0009</org_study_id>
    <nct_id>NCT03690141</nct_id>
  </id_info>
  <brief_title>An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)</brief_title>
  <official_title>A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effector Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Effector Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 Open-label Study examines the efficacy, safety, tolerability, and
      pharmacokinetics (PK) of tomivosertib (eFT508) in Patients with advanced CRPC.

      An Open-label Study Examining the Effect of tomivosertib (eFT508) in Patients with Advanced
      Castrate-resistant Prostate Cancer (CRPC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of
      tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on
      treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable
      curative therapy exists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Actual">April 27, 2020</completion_date>
  <primary_completion_date type="Actual">April 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>tomivosertib (eFT508) will be supplied as 100-mg capsules by the Sponsor. Capsules are packaged in 200-cc high-density polyethylene wide-mouth, round, white bottles, at either 100 or 150 units per bottle, induction sealed and capped with a 38-mm child-resistant closure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumor response as defined by a patient achieving either of the following outcomes:</measure>
    <time_frame>52 weeks</time_frame>
    <description>A ≥50% PSA decline from baseline at any time point after therapy and maintained for ≥4 weeks
Objective response according to iRECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA progression-free survival from start of study therapy until the date PSA progression is first observed.</measure>
    <time_frame>52 weeks</time_frame>
    <description>PSA progression is defined as a ≥25% increase in PSA from nadir or baseline (and by ≥2 ng/mL) and requires confirmation ≥3 weeks later.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Castrate-resistant Prostate Cancer (CRPC)</condition>
  <arm_group>
    <arm_group_label>tomivosertib (eFT508)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tomivosertib (eFT508)</intervention_name>
    <description>This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.</description>
    <arm_group_label>tomivosertib (eFT508)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men ≥18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Histologically or cytologically confirmed (by clinical site) adenocarcinoma of the
             prostate without neuroendocrine differentiation or small cell features.

          -  Ongoing androgen deprivation therapy with a GnRH analog or bilateral orchiectomy
             (surgical or medical castration).

          -  Serum testosterone ≤1.73 nmol/L (50 ng/dL) at screening.

          -  PSA progression on treatment with abiraterone and/or enzalutamide and/or apalutamide.
             PSA progression is defined by a minimum of 2 rising PSA levels with an interval of ≥1
             week between each determination. PSA value at the screening visit should be ≥2 ng/mL.
             Patients may also have:

               -  Soft tissue disease progression defined by iRECIST/RECIST 1.1

               -  Bone disease

          -  Patients receiving bisphosphonate/receptor activator of nuclear factor kappa-Β ligand
             (RANKL) therapy must have been on stable doses for ≥ 4 weeks before the start of study
             therapy.

          -  Completion of all previous therapy for the treatment of cancer ≥4 weeks before the
             start of study therapy.

          -  All acute toxic effects of any prior anti-tumor therapy resolved to Grade ≤1 before
             the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted],
             neurotoxicity [Grade 1 or 2 permitted], or bone marrow parameters [Grade 1 or 2
             permitted with exceptions as noted below]).

          -  Adequate bone marrow function:

               -  Absolute neutrophil count (ANC) ≥1.0 x 109/L

               -  Platelet count ≥75 x 109/L

               -  Hemoglobin ≥80 g/L (8.0 g/dL or 4.9 mmol/L)

          -  Adequate hepatic function:

               -  Serum alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN), ≤ 5 x ULN
                  in the presence of liver metastases

               -  Serum aspartate aminotransferase (AST) ≤3 x ULN, ≤5 x ULN in presence of liver
                  metastases

               -  Serum bilirubin ≤1.5 x ULN (unless due to Gilbert's syndrome or hemolysis ≤3 x
                  ULN)

          -  Adequate renal function:

             -Serum creatinine ≤1.5 mg/dL and/or creatinine clearance ≥30 mL/min using Cockcroft
             Gault equation (Appendix 13.4)

          -  For male patients who can father a child and are having intercourse with females of
             childbearing potential, willingness to use a protocol-recommended method of
             contraception from the start of study therapy and for ≥30 days following the last dose
             of study medication or to abstain from sexual intercourse for at least this period of
             time, and willingness to refrain from sperm donation from the start of study therapy
             to ≥90 days following the last dose of study drug.

          -  Estimated life expectancy &gt;12 weeks.

          -  Willingness to comply with scheduled visits, drug administration plan,
             protocol-specified laboratory tests and biopsies, other study procedures, and study
             restrictions. Note: Psychological, social, familial, or geographical factors that
             might preclude adequate study participation should be considered.

          -  Evidence of a personally signed informed consent indicating that the patient is aware
             of the neoplastic nature of the disease and has been informed of the procedures to be
             followed, the experimental nature of the therapy, alternatives, potential benefits,
             possible side effects, potential risks and discomforts, and other pertinent aspects of
             study participation.

        Exclusion Criteria:

          -  History of another malignancy except for the following: adequately treated local basal
             cell or squamous cell carcinoma of the skin; adequately treated, papillary,
             noninvasive bladder cancer; other adequately treated Stage 1 or 2 cancers currently in
             complete remission, or any other cancer that has been in complete remission for ≥2
             years.

          -  Rapidly progressive, clinically unstable central nervous system malignancy. Note:
             Central nervous system imaging is only required in patients with known or suspected
             central nervous system malignancy.

          -  Significant cardiovascular disease, including myocardial infarction, arterial
             thromboembolism, or cerebrovascular thromboembolism within 6 months before the start
             of study therapy; symptomatic dysrhythmias or unstable dysrhythmias requiring medical
             therapy; unstable angina; symptomatic peripheral vascular disease; New York Heart
             Association Class 3 or 4 congestive heart failure; Grade ≥3 hypertension (diastolic
             blood pressure ≥100 mmHg or systolic blood pressure ≥160 mmHg), or history of
             congenital prolonged QT syndrome.

          -  Significant screening electrocardiogram (ECG) abnormalities, including unstable
             cardiac arrhythmia requiring medication, left bundle-branch block, 2nd-degree
             atrioventricular (AV) block type II, 3rd-degree AV block, Grade ≥2 bradycardia, or
             QTcF ≥470 msec.

          -  Symptomatic or impending cord compression unless appropriately treated beforehand and
             clinically stable.

          -  Patients with gastrointestinal disorders likely to interfere with absorption of study
             medication.

          -  Major surgery within 4 weeks before the start of study therapy.

          -  Prior treatment with chemotherapy within 3 weeks or at least 4 half-lives, whichever
             is longer, before the start of study therapy.

          -  Prior therapy with any known inhibitor of MNK-1 or MNK-2.

          -  Treatment with 5-alpha reductase inhibitors within 4 weeks of enrollment.

          -  Prior flutamide treatment within 4 weeks before the start of study therapy and
             evidence of withdrawal response.

          -  Bicalutamide or nilutamide within 6 weeks before the start of study therapy and
             evidence of withdrawal response.

          -  Enzalutamide or abiraterone or apalutamid within 4 weeks before the start of study
             therapy.

             a. Steroids given in conjunction with abiraterone must be washed out for at least 2
             weeks prior to Cycle 1 Day 1 unless the investigator chooses to maintain at a dose of
             ≤10 mg/day prednisone or equivalent.

          -  Use of herbal products that may have hormonal anti-prostate cancer activity and/or are
             known to decrease PSA levels (eg, saw palmetto).

          -  Current use of immunosuppressive medication at the time of randomization, EXCEPT for
             the following:

               1. intranasal, inhaled, topical steroids, or local steroid injection (eg,
                  intra-articular injection);

               2. Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or
                  equivalent;

               3. Steroids as premedication for hypersensitivity reactions (eg, computed tomography
                  [CT] scan premedication).

          -  Use of a potent inhibitor or inducer of cytochrome P450 (CYP) 3A4 within 7 days before
             the start of study therapy or expected requirement for use of a CYP3A4 inhibitor or
             inducer during study therapy (Appendix 13.5).

          -  Concurrent participation in another therapeutic clinical trial.

          -  Any illness, medical condition, organ system dysfunction, or social situation,
             including mental illness or substance abuse, deemed by the investigator to be likely
             to interfere with a patient's ability to sign informed consent, adversely affect the
             patient's ability to cooperate and participate in the study, or compromise the
             interpretation of study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyon Gliech, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Urology</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Castrate-resistant Prostate Cancer</keyword>
  <keyword>CRPC</keyword>
  <keyword>eFT508</keyword>
  <keyword>eFT508-0009</keyword>
  <keyword>tomivosertib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

